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The majority of malignancies arising in the head and neck among patients with AIDS are Kaposi sarcoma and non-Hodgkin
lymphoma. Patients with HIV/AIDS are also at increased risk of developing several carcinomas of the head and neck. This
paper focuses on these less common, albeit important, carcinomas. An English language literature search identiﬁed numerous
population-based studies evaluating carcinomas in the head and neck of HIV-positive patients. Published results indicate that
patients with HIV/AIDS are at an increased risk of developing mucosal squamous cell carcinoma, nasopharyngeal carcinoma,
lymphoepithelial carcinoma of the salivary gland, and Merkel cell carcinoma in this anatomic region. Data also suggest that
HIV-positive patients with these cancers present at a younger age, with more aggressive disease and worse prognosis compared
to HIV-negative patients. Treatment involves surgical resection with or without radiation therapy and chemotherapy for locally
advanced andmetastaticdisease.AIDSpatients,however,aremorelikelytosuﬀerradiationtreatmentcomplications.Highlyactive
antiretroviral therapy (HAART) has not altered the incidence of these malignancies.
1.Introduction
An increased rate of neoplastic disease is a well-established
phenomenon in patients with human immunodeﬁciency
virus (HIV) and acquired immunodeﬁciency syndrome
(AIDS). In contrast to squamous cell carcinoma (SCC),
which is by far the most common head and neck malignancy
in HIV-negative patients, the majority of malignancies
arising in the head and neck among patients with AIDS are
the virally-induced AIDS-deﬁning cancers (ADCs): Kaposi
sarcoma (KS) and non-Hodgkin lymphoma (NHL), most
commonly large B-cell and plasmablastic lymphomas. How-
ever, as the HIV pandemic persists and more people are
living with chronic HIV infection, the spectrum of non-
AIDS deﬁning cancers (NADCs)seems to be increasing. The
incidence of NADC in the head and neck in patients with
HIV and AIDS is similalry increasing, including squamous
cell carcinoma (SCC), lymphoepithelial carcinoma (LEC) of
the salivary gland, nasopharyngeal carcinoma (NPC) and
Merkel cell carcinoma (MCC).
These aforementioned epithelial malignancies all dem-
onstrate a relationship to oncogenic viruses including
Human Papilloma virus (HPV), Epstein-Barr virus (EBV)
or Merkel cell polyoma virus (MCV). Since the oropharynx
and respiratory tract is a common site for the persistence
and transmission of these oncogenic viruses, it is possible
that patients with HIV/AIDS may be at increased risk of
developing head and neck cancers compared to the general
population. However, confounding etiologic factors also
exist since HIV-positive individuals generally have higher
smoking rates and greater alcohol consumption, both inde-
pendent risk factors for head and neck neoplasms, compared
to HIV-negative individuals [1–4]. This paper presents the
epidemiology, etiology, clinical features, pathologic ﬁndings,2 Pathology Research International
prognosis and management of the most commonly reported
epithelial NADC arising in the head and neck region of
patients with HIV/AIDS.
2.Methods
A literature review was performed using PubMed as well
as cited references within previously published articles and
textbooks for all published studies related to the incidence
of head and neck epithelial carcinomas (non-KS, non-NHL)
in patients with documented HIV infection. The study was
conﬁnedtoarticles inEnglish. Anattemptwas made toavoid
duplicate cases published in the literature. Standardized
incidence ratios (SIRs) and/or relative risks (RR), along
with 95% conﬁdence interval (95% CI)-were extracted and
tabulated.
3.Epidemiology
In the USA, approximately 36,540 individuals in the gen-
eral population are diagnosed yearly with head and neck
malignancies, and approximately 7,880 die of their illness
[5]. Epithelial malignancies of the head and neck are
most common in men over the age of 50 years and have
a strong association with cigarette smoking and alcohol
consumption. They are also associated with the oncogenic
viruses, EBV and HPV, typically in the nasopharynx and
oropharynx, respectively. In patients with HIV, a statistically
signiﬁcant increased risk has been reported for salivary
gland LEC and NPC as well as SCC of the lip, oropharynx,
and conjunctiva [4, 6–14]. Even though the results have
been variable [6, 8, 11, 13, 15–17], it appears that patients
with HIV present at a younger age, with more aggressive
disease and worse prognosis compared to their HIV-negative
counterparts [10, 11, 18–20].
4.Etiology
4.1. Immunosuppression. In comparison to patients with
HIV/AIDS, large population-based studies in immunosup-
pressed transplant recipients have demonstrated a wider
range of malignancies that may be associated with immun-
odeﬁciency. A meta-analysis comparing both HIV-positive
and HIV-negative immune suppressed patient groups
showed that an extensive range of malignancies occurred
at an increased incidence in both populations and that
the pattern of increased risk was similar [21]. Many of
these cancers are associated with a known infectious entity
including HPV, EBV, Human Polyoma virus, Hepatitis B
and C and others, and suggest that the range of infection-
related malignancies seen in immunodeﬁcient patients is
much wider than previously described. Of the HPV-related
malignancies, SCC of the lip, oral cavity, pharynx and
conjunctiva showed an increased incidence in HIV-negative
and HIV-positive immunosuppressed patient populations.
NPC seems to occur more commonly in patients with
HIV/AIDS, compared to transplant recipients. The SIR for
NPC arising in patients with HIV/AIDS was 2.90 (95%
CI 1.8–4.66) in people with HIV/AIDS. Only a single case
of NPC was reported in a transplant recipient [21]. It
is important to keep in mind that cigarette smoking is
diﬀerent in these two populations, with renal transplant
patients’ cigarette smoking rates being similar to the general
population[22] and more than doublethose ofpatientswith
HIV/AIDS[2].However,ameta-analysis ofSIRsfortobacco-
related cancers were not found to be consistently higher in
cohorts with HIV/AIDS [21].
In a large cohort study using nation-wide linkage data,
Grulich et al. [13] showed that patients with AIDS demon-
strate increased rates of several NADCs, whereas patients
with HIVandmildimmunodeﬁciencywereonlyatincreased
risk of anal cancer. Other cancers were seen only later in the
course of HIV-infection. These ﬁndings suggest that HIV-
positive patients with only mild immunodeﬁciency may not
be at an increased risk of NADCs. One study suggests that
theremay beincreased risk oforopharyngealcarcinoma with
increasing severity of AIDS-related immunodeﬁciency [10].
Since the introduction of highly active antiretroviral
therapy(HAART),mostHIV-positivepatientsarenowliving
with only mild to moderate degrees of immunodeﬁciency
for extended periods, and patients with AIDS now represent
an increasing minority. Thus, it is becoming increasingly
important to study the association between the degree and
duration of immunodeﬁciency and the risk of cancer. In
transplant recipients with prolonged immunosuppression,
there is a striking increased risk of HPV-related carcinomas
suggesting that even modest immunosuppression, if present
for a long period, can increase the risk of these cancers
[22]. Similar studies in mild-to-moderately immunodeﬁ-
cient HIV-positive patients receiving HAART are needed.
4.2. Oncogenic Viruses. The oropharyngeal compartment is
central to the persistence and transmission of both EBV
and HPV. Studies have shown that EBV and HPV are
more commonly detected in the oral mucosa of HIV-
positive patients compared to HIV-negative patients [23,
24]. Ammatuna et al. [23] detected EBV and HPV in the
oral mucosa of 17% and 3% of HIV-negative patients,
respectively, and 42% and 7% of HIV-positive patients.
Kreimer et al. [24] found similar results examining the
prevalence of oral high-risk HPV infection among HIV-
positive and HIV-negative patients (13.7% in HIV-positive
patients compared with 4.5% in HIV-negative patients).
The association between HIV and HPV in the context of
cervical cancer is well-established and it has been demon-
strated that the development and detection of cervical squa-
mous intraepithelial lesion (SIL) are directly proportional to
the severity of HIV-induced immunosuppression, measured
by low CD4 counts and high HIV viral loads [25, 26].
HPV, most commonly subtype 16, is responsible for some
oral cavity carcinomas, more than 60% of oropharyngeal
carcinomas, and approximately 90% of tonsillar carcinomas
[27–31].There are many otherstudieslinking HPVinfection
to SCC of the larynx and conjunctiva [32–34], and this
may also explain the increased risk of these carcinomas in
immunodeﬁcient patients [21, 27].Somestudieshave shown
that HPV-containing cancers of the head and neck lack p53
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[35–37]. It is well established that the E6 protein of HPV
16 inactivates p53 protein, an important component of the
cell cycle, which leads to increased rates of mutagenesis.
Thus, the pathogenesis of HPV-associated SCC of the head
and neck in patients with HIV/AIDS includes increased
proliferation of neoplastic cells caused by viral interference
with tumor suppressor genes(p53 and retinoblastoma) from
viral proteins generated by both HIV and HPV [35–39].
While AIDS patients have been shown to be at increased risk
of developing HPV-associated oropharyngeal carcinomas
(SIR 1.6, 95% CI 1.2–2.1), it is possible that confounding
factorssuchasincr easedcigar ettesmokingratesma yaccount
for some of this increased risk [10].
Following primary infection with EBV, this herpes virus
may undergo active lytic replication releasing viral progeny
or may initiate active latency in which one of three restricted
gene expression programs is initiated. Type I latency with
expression of only EBER (EBV early RNAs) and EBNA-
1 (EBV nuclear antigens) is typical of Burkitt lymphoma.
Type IIlatency demonstrates theexpression ofEBER,EBNA-
1, and latent membrane proteins (LMPs) and is seen in
nasopharyngeal carcinoma. Both latency patterns I and II
have been identiﬁed in LEC of the salivary gland. EBV is
also associated with a variety of other epithelial carcinomas
including LEC of the stomach, lung and thymus [35]. EBV
has also been implicated in the chronic inﬂammatory condi-
tion known as HIV-related sialadenitis. Chronic sialadenitis
is also known to be a risk for salivary gland carcinoma
[35]. It has been suggested that altered immunity may be
important for the developmentof EBV-related salivary gland
carcinomas since they have also been described in patients
with chronic autoimmune disease [40].
MCC also commonly aﬀects immunocompromised
patients, suggesting infectious etiology. With great excite-
ment,theassociation with MCV (alsoreferred toas MCPyV)
was recently established [41]. In MCC, the viral DNA is
integrated into the tumor genome in a clonal manner [41].
This suggests that infection and integration of the MCV
occurs prior to the clonal expansion of the tumor cells and
implicates this virus in the pathogenesis of MCC. Once
inserted into the host DNA, viral T antigen is expressed as
large T and small T antigens. These T antigens in turn alter
the behavior of tumor suppressor and cell cycle regulatory
proteins such as Rb, p53, protein phosphatase 2A, and
Bub1 [42]. Other risk factors including increased exposure
to ultraviolet (UV) and ionizing radiation may also be
involved in T-antigen mutations. Although MCV may be
present in cutaneous MCC, it has not been found in similar
mucosal high-grade neuroendocrine carcinomas [43]. On
the other hand, common warts can be positive for MCV in
immunosuppressed individuals [44], but not SCC or basal
cell carcinoma (BCC) of the skin [45].
4.3.NonviralCofactors. Thereisastrongassociationbetween
head and neck SCC and cigarette smoking and heavy alcohol
consumption. In fact, these two risk factors are strongly
synergistic and may account for approximately 75% of these
SCCs [46]. There are numerous studies demonstrating that
smoking ismore commonin HIV-positive persons [1–4,47],
which may explain the increased rates of head and neck
carcinomas, especially SCC in this population. However,
it is unlikely that cigarette smoking alone can explain the
statistically signiﬁcant increased rates of head and neck
SCC observed arising in HIV infected patients signiﬁcantly
youngerthantheirHIV-negativecounterparts[10,11,14,18,
19, 48]. In a prospective study out of France, 11% of deaths
in HIV positive patients resulted from cancers not caused by
hepatitis and unrelated to HIV, and in these cases, smoking
and excess alcohol consumption were recorded in 72% and
27% of these cancer deaths respectively [49]. In keeping with
these ﬁndings, Cliﬀord et al. in a retrospective study from
Switzerland found a threefold excess in carcinomas ofthe lip,
mouth, pharynx and lung in HIV-positive patients, and that
no carcinomas from these siteswere observedin nonsmokers
[4]. UV light exposure is another important risk factor for
SCC of the lip [7, 9, 12, 46]. Other potential carcinogenic
factorsrelatedtooralSCCaremarijuana, syphilis,oralsepsis,
iron deﬁciency, and oral candidiasis.
5.M ucosalSquamousCellCarcinoma
SCC of the head and neck comprises a heterogenous group
of neoplasms arising from the mucosa of the oral cavity,
oropharynx, hypopharynx, larynx, and other sites. The most
commonly reported sites for SCC include the oropharynx,
conjunctiva, tonsil, and larynx (see Table 1), which is
consistent with other studies [27, 38, 50, 51]. Interestingly, a
studyfromKenyadescribedan8%prevalenceofconjunctival
SCC in patients with HIV/AIDS [51]. A number of epidemi-
ological studies have identiﬁed an increased risk of SCC of
the larynx, oral cavity, oropharynx, lip, salivary gland, and
conjunctiva in HIV-positive patients (see Table 2)[ 7, 10,
12, 14, 16, 21, 26, 27, 50]. Shebl et al. [14]d e m o n s t r a t e d
increased rates of HIV-related SCC of the salivary gland (SIR
4.9, 95% CI 2.5–8.6). It must be noted, however, that many
so-called SCC of the salivary gland may represent metastases
from other head and neck sites. A statistically signiﬁcant
increased risk of oropharyngeal, conjunctival and tonsillar
SCC has also been shown in patients with AIDS (Table 2)
[7, 9, 10, 12]. As in the general population, SCC of the oral
cavity in patients with AIDS may present as an ulcerated or
fungating mass or as erythroplakia [10, 20]. Data regarding
the incidence and risk of mucosal SCC precursor lesions
in patients is limited. However, it is likely that the clinical
distinction between benign conditions (e.g., aphthous or
infectious ulcers), neoplastic erythroplakia and SCC may
be challenging. Most of the aﬀected HIV-positive patients
reported to date presented at a younger age and advanced
stage at presentation [10, 11, 18, 19, 48]. In general, an
overall younger age at presentation has been reported for
HIV-associated SCCoftheheadandneck[10,11,18,19,48].
One study demonstrated a mean age of 36 years [18].
The histopathologic features of SCCs arising in the
head and neck range from well diﬀerentiated tumor with
obvious squamous diﬀerentiation and keratinization to
poorly diﬀerentiated carcinomas lacking keratinization (see
Figure 1). Keratinizing carcinomas are more typical of the
oral cavity and larynx, whereas nonkeratinizing morphology4 Pathology Research International
(a) (b)
(c) (d)
Figure 1: (a) and (b) Squamous cell carcinoma in situ of the conjunctiva in a 43-year-old HIV-positive man. ((a) hematoxylin & eosin
(H&E) stain,100xmagniﬁcation;(b)H&E stain,400xmagniﬁcation).(c)and(d)Ulcerated (c)invasivemoderatelydiﬀerentiated squamous
cell carcinoma of the tongue and inﬁltrating among skeletal muscle bands (d) in a 54-year-old HIV-positive man ((c) H&E stain, 100x
magniﬁcation;(d) H&E stain, 200x magniﬁcation).
Table 1: Sites of conﬁrmed mucosal SCC in The head and neck in
patients with HIV/AIDS in articles reviewed.
Site Number of cases Reference
Oropharynx 68 [10, 27]
Conjunctiva 65 [7, 9, 12, 38, 39]
Tonsil 29 [9]
Larynx 18 [8, 27]
Oral Cavity 14 [16, 18, 27]
Lip 13 [16]
is seen more commonly in the oropharynx, the latter of
which is associated with HPV (see Figure 2). While several
morphologic variants of SCC (e.g., verrucous, basaloid,
and spindle cell carcinoma) exist, these have not been
documented to have a diﬀerent incidence in the setting
of HIV as compared to the general population. A recent
study by McLemore et al. [27] described the presence of
multinucleated tumor giant cells in 39 of 40 head and
neck SCC arising in patients with HIV/AIDS. This feature
has not been previously reported. We reviewed cases of
mucosal SCC in HIV-positive patients from our institution
and also identiﬁed these multinucleated tumor giant cells
(see Figure 3). Otherwise, the morphologic features of SCCs
in HIV patients are not particularly distinct despite the
aggressive clinical behavior in this setting.
SCCof theconjunctivaisfar morecommonamong HIV-
infected individuals compared to HIV-negative persons. A
dramatic increase in conjunctival SCC has been reported
in sub-Saharan Africa as well as North America [12, 52].
The lower incidence in Europe is believed to be due to the
lower solar UV exposure associated with higher latitudes.
HIV-related conjunctival squamous lesions range from
intraepithelial dysplasia, to carcinoma in situ and invasive
SCC. Conjunctival SCC can be seen in relatively young
HIV-positive patients and these cancers may be aggressive.
Patients can present with eye irritation, erythema, plaque
or tumor nodule. SCC of the conjunctiva also has a high
propensity for local invasion into the orbit, and occasionally
distant metastases may occur. The most common site of
origin is the limbus or transition zone of the eye. A case
report described conjunctival SCC arising in a 38-year-
old woman that although it was focally keratinized, her
carcinoma was unusual in that it demonstrated multifocality
[51]. In a hospital-based cross-sectional study from Kenya,
Chisi et al. [53] noted the following prevalence of histologic
patterns of conjunctival SCC in patients with HIV/AIDS:
47% of cases were poorly diﬀerentiated, 28% moderately
diﬀerentiated,3% were well diﬀerentiatedand the remainder
of these lesions were in situ [53].
Localized SCC is managed with surgery and/or radi-
ation therapy depending on the anatomic subsite. For
more extensive or recurrent lesions systemic or targeted
chemotherapy may be considered. Treatment complications
such as secondary candidiasis and oral mucositis were more
commonand severeinHIV-positive patients[16,54, 55]an d
the outcome of these patients was signiﬁcantly worse [56].
However, Kao et al. showed that HIV-positive patients could
still tolerate radiation therapy [57]. HAART therapy has notPathology Research International 5
(a) (b)
Figure 2: Detection of HPV by immunohistochemistry for p16 ((a) 400x magniﬁcation) and HPV in situ hybridization ((b) 400x
magniﬁcation) in a nonkeratinizing squamous cell carcinoma of the tonsil. Note the strong diﬀuse nuclear and cytoplasmic staining with
p16 immunohistochemical stain (a) and the focal nuclear dot positivity with HPV in situ hybridization, conﬁrming the presence of HPV
within the tumor.
(a) (b)
(c) (d)
Figure 3: Example of the multinucleated tumor giant cells in mucosal squamous cell carcinoma arising in the tongue (a) of a 48 year old
HIV-positive man, in the tongue (b) of a 54-year-old HIV-positive man and in the oral cavity (c, d) of a 44-year-old HIV-positive man and,
similar to the ﬁndings of McLemore et al. [27] ((a)–(d) H&E stain, 400x magniﬁcation).
altered the incidence of SCC of the oropharynx and other
head and neck sites [4, 10, 16, 58, 59].
6.Salivary-Type Carcinomas
Some studies [6, 14], but not all [13], have shown that
patients with HIV are at increased risk of developing salivary
gland malignancies (see Table 2). Among salivary gland
malignancies, theriskofcommonhistologicsubtypesseenin
the general population such as mucoepidermoid carcinoma,
adenoid cystic carcinoma and adenocarcinoma, was not ele-
vated among AIDSpatients [14]. However, for LEC and SCC
ofthesalivary gland,theriskwas greatlyincreased inpatients
with AIDS (SIR 39, 95% CI 16.0–81.0 and SIR 4.9, 95% CI
2.5–8.6 resp.) compared to the general population [14].
The cancer risk for patients with HIV was greatest with
LEC. However, a signiﬁcant risk was also determined for
SCC of the salivary gland. Whenever a diagnosis of primary
SCC of the salivary gland is considered, it is crucial to
rule out a metastatic process from another more common
head and neck site to a lymph node within or adjacent to
the salivary gland [60]. Coincidentally, the parotid gland in
which numerous intraparotid lymph nodes can be found is
the most commonly reported site of the so-called primary
SCCs of the salivary gland. Histologically, the vast majority
of SCC in the salivary gland tend to be high-grade and
keratinizing[60].Uniquehistologicfeaturesofsalivary gland6 Pathology Research International
Table 2: Incidence of head and neck carcinomas arising in patients with HIV and AIDS.
Ref # Year Country # patients # Cases Cancer site (Subtype) SIRs or RR (95% CI) HIV/AIDS
[4] 2005 Switzerland 7304 11 1 Lip, 4 tongue, 4 mouth, 1
pharynx, 1 NPC (?) SIR =4.1(2.1–7.4) not speciﬁed
[6] 1999 S. Europe 5281 2S G ( ? ) SIR =33.6(3.2–123.5) AIDS
1N P C S I R = 10.3 (0.0–58.8) AIDS
[7] 2006 Uganda 12,607 3T h y r o i d SIR =5.7(1.1–16.0) Not speciﬁed
6 Conjunctiva (SCC) SIR =4.0(1.5–8.7) Not speciﬁed
[15] 1996 USA 50,050 4 NPC (2 SCC + 2 LEC) RR = 2.4 (0.7–6.2) AIDS
[8] 2002 Australia
8118 6 Lip (SCC) SIR = ∼6( ∼2–9.5)∗ HIV
8118 6 Lip (SCC) SIR = ∼6.9 (∼1.8–9.6)∗ HIV
7061 4 Lip (SCC) SIR = ∼3.0 (0.8–8.1)∗ HIV
2112 3 Lip (SCC) SIR = ∼9.0 (∼3.0–>10)∗ AIDS
[16] 2004 UK 8640 7 2 NPC; 3 oral cavity (SCC)
2 larynx (SCC) SIR = 1.66 (0.67–3.42) 2( A I D S ) ;5
(HIV)
[9] 2000 USA 309,365 29 Tonsil (SCC) RR =2.6(1.8–3.8) HIV/AIDS
7 Conjunctiva (SCC) RR =14.6(5.8–30.0)
[17] 2003 Scotland 2574 1 H&N (unspeciﬁed, not KS) SIR = 1.6 (0.04–8.8) Unknown
[10] 2009 USA 499,230 59 Oropharynx (SCC) SIR =1.6(1.2 to2.1) AIDS
[11] 2005 England
33,190
6O r a l ( ? ) S I R = 1.1 (0.4–2.3) HIV
4N P C ( ? ) SIR =5.0(1.4–12.8) HIV
1 NasalCavity (?) SIR = 1.7 (0.04–9.4) HIV
5L a r y n x ( ? ) S I R = 2.0 (0.7–4.8) HIV
12126
5O r a l ( ? ) SIR =3.8(1.2–8.8) AIDS
1N P C ( ? ) S I R = 5.8 (0.1–32.5) AIDS
1 NasalCavity (?) SIR = 7.9 (0.2–44.0) AIDS
2L a r y n x ( ? ) S I R = 3.2 (0.4–11.6) AIDS
[12] 2008 USA 491,048 15 Conjunctiva (SCC) SIR =12.2(6.8–20.2) AIDS
[13] 2002 Australia 13,067
10 Lip (?) SIR =2.26(1.08–4.16) Not speciﬁed
2T o n g u e ( ? ) S I R = 1.66 (0.20–5.99) Not speciﬁed
2S G ( ? ) S I R = 3.88 (0.47–14.0) Not speciﬁed
2N a s o p h a r y n x ( ? ) S I R = 2.74 (0.33–9.89) Not speciﬁed
1 Nose/sinuses/ear (?) SIR = 2.97 (0.08–16.5) Not speciﬁed
1L a r y n x ( ? ) S I R = 0.60 (0.02–3.34) Not speciﬁed
1 Eye (?) SIR = 1.73 (0.04–9.64) Not speciﬁed
1T h y r o i d ( ? ) S I R = 0.56 (0.01–3.12) Not speciﬁed
[14] 2009 USA 519,934
43 SG (All types) SIR =1.8(1.3–2.4) AIDS
12 SG (SCC) SIR =4.9(2.5–8.6) AIDS
7S G ( L E C ) SIR =39(16–81) AIDS
6S G ( A c i n a r c e l l c a ) S I R = 1.9 (0.7–4.1) AIDS
5S G ( M E C ) S I R = 0.6 (0.2–1.5) AIDS
2S G ( A d e n o i d C y s t i c C a )S I R = 0.6 (0.1–2.0) AIDS
2S G ( A d e n o c a ) S I R = 0.7 (0.1–2.5) AIDS
39 NPC (All types) SIR =2.0(1.4–2.7) AIDS
22 NPC (Ker SCC) SIR =2.4(1.5–3.7) AIDS
10 NPC (NK Carc) SIR =2.4(1.2–4.4) AIDS
5N P C ( L E C ) S I R = 2.1 (0.7–4.9) AIDS
5 NPC (NK SCC) SIR = 2.8 (0.9–6.6) AIDS
7N P C ( O t h e r / ? ) S I R = 1.1 (0.5–2.3) AIDS
Bold values indicate cancer sites where the 95% conﬁdence interval does not include one.
SIR:standardizedincidenceratio,RR: relative risk,SG:salivarygland, SCC:squamouscell carcinoma, NK: nonkeratinizing,NPC: nasopharyngeal carcinoma,
H&N: head and neck, Ker: keratinizing, LEC: lymphoepithelial carcinoma, Adenoca: Adenocarcinoma.Pathology Research International 7
(a) (b)
(c) (d)
Figure 4: Lymphoepithelial carcinoma of the parotid gland. (a) Medium power view demonstrating the associationbetween the high grade
neoplasm and the parotid acini (H&E stain, 100x magniﬁcation). (b) High power view showing the highly atypical epithelial cells with
irregular vesicular nuclei and prominent nucleoli (H&E stain, 400x magniﬁcation). (c) A cytokeratin AE1 and AE3 highlighting the high
grade epithelial cells (200x magniﬁcation).(d) EBER in situ hybridization demonstratingstrong diﬀuse nuclear reactivity. Image courtesy of
Dr. E. Leon Barnes (400x magniﬁcation).
carcinoma in patients infected with HIV have not been
described.
For patients with HIV, the greatest risk for salivary gland
carcinoma was determined to be the LEC subtype [14].
The WHO [60] deﬁnes LEC of the salivary gland as an
undiﬀerentiated carcinoma accompanied by a prominent
non-neoplastic lymphoplasmacytic inﬁltrate. It comprises
less than 1% of all salivary gland tumors arising in the
general population and is mos tc o m m o ni nI n u i t( E s k i m o )
and Asian populations. EBV is associated with almost 100%
ofLEC casesfrom endemicareas however, it isusually absent
in salivary gland LEC from nonendemic areas. EBV isolated
from salivary gland LEC from endemic areas reveals the
presence of a clonal episomal form of the virus. LEC of the
salivary gland developsas a result ofa complex interaction of
ethnic, geographic and viral factors [60]. LEC tends to arise
de novo however it can rarely arise from lymphoepithelial
sialadenitis. Morphologically, salivary gland LEC is
indistinguishable from the more common nasopharyngeal
carcinoma (NPC). As with SCC in the salivary gland, the
vast majority of LEC are diagnosed within the parotid gland
[60].
Histologically, the malignant cells of LEC are arranged
in inﬁltrative sheets and islands with abundant lymphoid
stroma consistingofpolymorphouslymphocytesandplasma
cells (see Figure 4). Tumor cells have indistinct borders with
pale eosinophilic cytoplasm and variable vesicular nuclei
with prominent nucleoli. Apart from NPC, other malignant
entities to consider in the diﬀerentiation include malignant
lymphoma and undiﬀerentiated carcinoma. Mitoses are
common in LEC and so are necrotic foci. Focal squamous
diﬀerentiation can be seen. Less common features include
noncaseating granulomas, multinucleated giant cells, amy-
loid and cystic structures. Perineural and angiolymphatic
invasion may be seen. The tumor cells are immunoreactive
for pancytokeratin and epithelial membrane antigen (EMA).
Salivary glandLECarising inendemicareastypicallydemon-
strate positivity for EBER (see Figure 4).
Both LEC and SCC of the salivary gland are typically
treated with surgery and radiation therapy for localized
disease. Systemic chemotherapy may be utilized for wide-
spread or metastatic disease. Survival is based on stage of
disease, with lower stages demonstrating greater 5-year sur-
vival. However, as discussed above, patients with profound
immunosuppression will likely poorly tolerate surgery,
radiation and/or chemotherapy.
7.Nasopharyngeal Carcinoma
In one of the earlier studies, no increased risk of NPC was
seen in patients with AIDS in the USA [15]. In a total of
50,050patientswithAIDS,only4NPCwerediagnosed.Later
studies such as that reported by Frisch et al. did demonstrate
an increased risk of NPC in AIDS patients (SIR 2.6, 95%
CI 1.8–3.8) [9]. The most recent comprehensive study by
Shebl et al. also demonstrated an increased risk for NPC for
all histologic subtypes (SIR 2.0, 95% CI 1.4–2.7) [14]. The
highest SIR in their paper was calculated for nonkeratinizing8 Pathology Research International
(a) (b)
Figure 5:(a) Medium-power view ofa nasopharyngealcarcinoma,nonkeratinizing,undiﬀerentiated type (H&E stain,200x magniﬁcation).
(b) High-power view demonstrating the high-grade malignant cells with indistinct cytoplasmic borders, irregular nuclei with prominent
nucleoli (H&E stain, 400x magniﬁcation).
(a) (b)
(c) (d)
Figure 6: (a) Low-power view of Merkel cell carcinoma arising in a transplant patient. Note the hypercellular proliferation of small blue
cells within thedermis (H&E stain,40xmagniﬁcation).(b) A cytokeratinstain(CAM5.2)demonstratingstrongdiﬀuse cytoplasmicstaining
(400x magniﬁcation). (c) Perinuclear positivity is seen with cytokeratin 20 (400x magniﬁcation). (d) Synaptophysin demonstrates diﬀuse
cytoplasmic staining.
SCC of the nasopharynx (SIR 2.8, 95% CI 0.9–6.6), followed
by nonkeratinizing carcinoma of the nasopharynx (SIR 2.4,
95% CI 1.2–4.4), keratinizing NPC (SIR 2.4, 95% CI 1.5–
3.7), LEC of the nasopharynx (SIR 2.1, 95% CI 0.7–4.9) and
othersubtypes(SIR1.1,95% CI0.5–2.3)(seeTable 2).Other
studies, but not all, have also demonstrated an increased
risk of NPC, and the variability among these studies most
likely relates to the rarity of this neoplasm in all populations
[6, 11, 13, 16, 18].
The WHO deﬁnes NPC as a carcinoma arising in the
nasopharyngeal mucosa that shows light microscopic or
ultrastructural evidence of squamous diﬀerentiation. It
encompasses keratinizing SCC, nonkeratinizing carcinoma
(diﬀerentiated or undiﬀerentiated) and basaloid SCC.
Adenocarcinoma and salivary-gland-type carcinoma are
excluded [62]. The most common site of origin is the lateral
wall of the nasopharynx, followed by the superior posterior
wall [62]. The histopathologic features (see Figure 5) depend
on the histologic subtype but should demonstrate evidence
of squamous diﬀerentiation either by light or electron
microscopy. Close to 100% of patients with nonkeratinizing
NPC demonstrate positivity for EBV, whereas keratinizing
SCC or NPC demonstrates more conﬂicting results. These
tumors are immunoreactive for pancytokeratins (AE1/AE3)
and high-molecular weight cytokeratins (cytokeratin 5/6,
34βE12) [62].Pathology Research International 9
Table 3: Merkel cell carcinoma in head and neck sites of HIV positive patients (reproduced from Izikson et al. [61]).
Sex Race Age
(years) Site HIV Dx to MCC
(years)
CD4
(cells/μL)
Viral load
(copies/mL) Treatment On HAART Survival
(months)
MN A 6 0 N o s e N A329 (2yrs
after Dx) NA Mohs XRt Yes 24
M NA 63 Forehead 12 232 Undetectable Mohs Yes NA
F African black 36 Left ear NA 63 24,000 WLE Yes >9
F African black
albino 25 Right cheek NA 332 187,000 Chemo, XRt, WLE Yes (after Dx) 12
M Caucasian 48 Scalp 12 Normal Undetectable WLE, XRt Yes >12
Dx: diagnosis, XRt: radiation therapy, NA: not available, Chemo.: chemotherapy, WLE: wide local excision.
Radiation therapy is the treatment of choice for NPC,
albeit that a greater incidence of treatment related mor-
bidities has been reported in patients with HIV infection
[16, 54, 55]. As expected, outcomeand prognosis are directly
related to the stage of carcinoma, with lower stages having a
much better outcome.
8.Merkel CellCarcinoma
MCC is a rare neuroendocrine carcinoma of the skin most
commonly occurring in elderly men. It is very aggressive
with a high frequency of local recurrence and metastases.
In immunocompetent individuals, MCC tends to arise in
sun-exposed areas, with approximately 50% arising in the
head and neck region, especially the periorbital areas [63]. A
recentdevelopmentintheunderstandingofthepathogenesis
of MCC is the discovery of the MCV [41]a n dt h e r e
is evidence that conditions causing immunosuppression,
including HIV, are important risk factors [64]. Engels et
al. calculated a relative risk of 13.4 (95% CI 4.9–29.1) of
developing MCC in patients with HIV/AIDS compared to
the general population [64]. Primary MCC may also arise
in non-cutaneous sites in HIV-positive patients, such as
intraparotid lymph nodes [65].
The histologicfeaturesofMCCin immunocompromised
and immunocompetent are identical, with hypercellular
areascomposed of“small bluecells” with indistinct cytoplas-
mic borders, hyperchromatic nuclei with indistinct nucle-
oli and numerous mitotic and apoptotic bodies scattered
throughout the tumor (see Figure 6). Angiolymphatic inva-
sion and surface ulceration may be seen [63]. MCC must be
distinguished from other small round blue cell tumors such
as small cell carcinoma of the lung and lymphoma. MCC
demonstrates immunoreactivity for both neuroendocrine
markers (neuron speciﬁc enolase, synaptophysin and chro-
mogranin) and cytokeratins (cytokeratin 20 and CAM5.2)
(see Figure 6). Paranuclear dot-like positivity with cytok-
eratin 20 is useful diagnostic feature (see Figure 6). MCC
is negative for TTF-1, cytokeratin 7 and LCA which help
to distinguish this neuroendocrine tumor from small cell
carcinoma of the lung and lymphoma. Many cases of MCC
may demonstrate CD117 (c-kit) positivity, however this has
not been associated with improved outcome [63, 66]. Thus
far, no c-kit-activating mutations have been identiﬁed [66].
In a recent review article, Izikson et al. [61]r e v i e w e dt h e
clinical characteristics of 11 HIV-positive patients with MCC
identiﬁed from a literature review, along with 3 additional
newcases. UnlikeMCC sitesinimmunocompetent individu-
als which tendstoarise insun-exposed areas, MCC sites were
muchmore diverseandin non-sun exposedareas, suggesting
that UV radiation may be less important in the pathogenesis
of MCC in immunocompromised HIV-positive individuals.
Of the 14 cases reviewed, 5 patients were diagnosed with
MCC of the head and neck region (see Table 3). Sites were
MCC was documented included the nose, forehead, ear,
cheek and scalp. The average age at diagnosis for all 14 cases
was 49 years and for the 5 cases arising in the head and neck,
the average age was 46.4 years, both much younger than the
average age of 69 years seen in immunocompetent individ-
uals [61]. The range for CD4 count was 63–329cells/μLa n d
the HIV viral load was undetectable to 187,000 copies/mL in
some patients (see Table 3). There does not appear to be a
relationship between CD4 cell count and HIV viral load with
regard to MCC. All 5 patients received HAARTprior to, or in
one case following the diagnosis of MCC. The lesions in all 5
patients were surgically excised and some received additional
radiation and/or chemotherapy. Their survival ranged from
9–24 months.
9.Conclusion
As HIV-positive patients live longer with chronic HIV
infection we can anticipate an increase in NADC-like
head and neck carcinoma. The head and neck carcinomas
reviewed here not only demonstrate an increased risk in
HIV-positive patients, but all have in common a known
oncogenic viral association. It is well established that
virally induced neoplasms occur with increased frequency in
immunosuppressedindividuals.Studiescomparingcancerin
other immunocompromised populations, such as transplant
recipients, to patients infected with HIV may allow us
to better determine which of these carcinomas are truly
related to immune deﬁciency. However, larger cohort studies
are required to fully investigate the risks of NADC in
patientswith HIVinfection. The youngerage at presentation
mandates early screening for carcinomas arising in the head
and neck of HIV-positive patients. However, clinical staging
of a detected carcinoma poses a challenge since lymph node10 Pathology Research International
enlargement in the head and neck is common among HIV-
positive patients due to a variety of other reasons.
Further investigations are required to explore the patho-
genesis, biology and management in HIV-positive patients
with head and neck carcinomas. management of patients
with AIDS and head and neck cancer is particularly dif-
ﬁcult given that many of these patients may not tolerate
chemotherapy or radiation therapy and may also have a
greater surgical complication rate [16, 54]. However, since
the introduction of HAART, patients with advanced AIDS
are becoming a minority and as a result of improved
immunity with HAART, there are increased therapeutic
options for infected individuals with cancer. There is little
information regarding the impact of HAART on SCC of
the oropharynx and other head and neck carcinomas. Based
upon available data, however, it appears that HAARThas not
altered the incidence of head and neck carcinomas in HIV-
positive patients as is seen with KS [4, 10, 16, 58–60, 62].
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